{ "docId": "019de072-75de-708e-aad9-55788df6c953", "docSlug": "5188528054c3088b6a98b04815eb3ce3", "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-04-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "pageCount": 40, "prevPage": 16, "nextPage": 18, "slideType": "key_messages", "function": "summarize", "density": "overcrowded", "nDataPoints": 0, "notes": "The slide uses a three-column layout to summarize distinct therapeutic areas.", "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/17", "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953", "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json", "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-17", "components": [ { "bbox": { "h": 0.08, "w": 0.28, "x": 0.05, "y": 0.78 }, "kind": "callout", "text": "Building the next generation of PARP inhibitors", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "317d7790-2b2a-4a9a-9e49-0c761620eb10", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.67, "y": 0.78 }, "kind": "callout", "text": "Showcasing our in-house next-wave ADC capabilities", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7df69e68-ad98-494a-94de-cfd78e2b3660", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.67, "y": 0.5 }, "kind": "image", "text": "ADC mechanism diagram", "attrs": null, "subkind": "illustration", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4a9283e0-97b6-4d0c-8197-8616f87f1386", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.36, "y": 0.5 }, "kind": "image", "text": "Bispecific antibody diagram", "attrs": null, "subkind": "illustration", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6da7c85b-ec0b-46fb-9d89-14ed8ad231c6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.05, "y": 0.5 }, "kind": "image", "text": "DDR mechanism diagram", "attrs": null, "subkind": "illustration", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f4a1598f-ec74-4f9f-800a-184acc0664a9", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.12, "x": 0.85, "y": 0.02 }, "kind": "image", "text": "AACR Annual Meeting 2022", "attrs": null, "subkind": "logo", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6e506dfb-e222-42e8-b647-618f4c4c12f6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.67, "y": 0.25 }, "kind": "paragraph", "text": "ADC: AZD8205 B7-H4 TOP1i. Preclinical data from ADC targeting B7-H4; first ADC to use AZ's proprietary linker technology", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2e623cad-4ee1-4ea9-8487-94147fbd2f37", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.36, "y": 0.25 }, "kind": "paragraph", "text": "IO: MEDI5752 PD-1/CTLA-4. Phase I data for bispecific designed to enhance CTLA-4 blockade on PD-1+-activated T cells", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9a01ab51-9cda-4c48-beef-e064d1c3d815", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.05, "y": 0.25 }, "kind": "paragraph", "text": "DDR: AZD5305 ngPARP1-sel. PETRA: Phase I data for next-gen PARP1-selective targeting tumour cell DDR mechanisms.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ed630647-da42-4cb0-b920-1325ed7aa967", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.96, "x": 0.02, "y": 0.95 }, "kind": "source-note", "text": "AACR = American Association for Cancer Research; DDR = DNA damage response; ng = next generation; PARP = poly (ADP-ribose) polymerase; sel = selective; IO = immuno-oncology; PD-1 = CTLA-4 = cytotoxic T-lymphocyte associated protein 4; IgG1 = immunoglobulin G1; ADC = antibody drug conjugate; B7-H4 = B7 homolog protein 4; TOP1i = topoisomerase I inhibitor.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e8b93bfb-a170-465e-b77f-3b9839fba358", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.45, "x": 0.03, "y": 0.13 }, "kind": "title", "text": "Pioneering science previewed at AACR 2022", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e300903b-a0e3-41f3-b4c4-6accbca17a8d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Oncology: Q1 2022 R&D highlights", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "13d8521f-d3eb-4b11-b7c2-33312b077fce", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "from": 11, "beatId": "9033f2c1-0a31-4be1-9e9e-1cfab54f34ea", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The slides showcase the company's achievements in Oncology, BioPharmaceuticals, and Rare Disease", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "loops": [ { "to": 20, "from": 16, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "a11d4c4b-770f-4828-bf13-5681ad15110b", "evidence": "The slides preview pioneering science and highlight R&D achievements", "position": 1, "objective": "Explaining the company's scientific leadership", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }